EBS Stock - Emergent BioSolutions Inc.
Unlock GoAI Insights for EBS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.04B | $1.05B | $1.12B | $1.77B | $1.58B |
| Gross Profit | $375.40M | $360.00M | $473.00M | $793.20M | $863.10M |
| Gross Margin | 36.0% | 34.3% | 42.3% | 44.7% | 54.7% |
| Operating Income | $-108,700,000 | $-726,400,000 | $-170,000,000 | $341.40M | $438.50M |
| Net Income | $-190,600,000 | $-760,500,000 | $-211,600,000 | $219.50M | $305.80M |
| Net Margin | -18.3% | -72.5% | -18.9% | 12.4% | 19.4% |
| EPS | $-3.60 | $-14.85 | $-4.47 | $4.10 | $5.79 |
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 30th 2024 | H.C. Wainwright | Initiation | Buy | $15 |
| August 22nd 2024 | Rodman & Renshaw | Initiation | Buy | $16 |
| March 7th 2024 | The Benchmark Company | Upgrade | Buy | $5 |
| November 20th 2023 | JP Morgan | Resumed | Underweight | - |
| August 29th 2023 | The Benchmark Company | Downgrade | Hold | - |
| April 10th 2023 | The Benchmark Company | Upgrade | Buy | $22 |
| March 17th 2023 | JP Morgan | Downgrade | Underweight | $9← $23 |
| November 10th 2022 | The Benchmark Company | Downgrade | Hold | - |
| April 29th 2022 | Cantor Fitzgerald | Downgrade | Neutral | - |
Earnings History & Surprises
EBSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | — | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.12 | $1.06 | +983.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.26 | $0.16 | +161.5% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.49 | $0.71 | +44.9% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.35 | $0.05 | +114.3% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.49 | $1.37 | +179.6% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.97 | $-2.32 | -139.2% | ✗ MISS |
Q2 2024 | May 1, 2024 | $-0.86 | $0.59 | +168.6% | ✓ BEAT |
Q1 2024 | Mar 6, 2024 | $-0.33 | $-0.77 | -133.3% | ✗ MISS |
Q4 2023 | Dec 11, 2023 | $-0.12 | $-1.44 | -1100.0% | ✗ MISS |
Q4 2023 | Dec 11, 2023 | — | $-1.76 | — | — |
Q3 2023 | Aug 8, 2023 | $-0.98 | $-1.06 | -8.2% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | — | $-5.15 | — | — |
Q2 2023 | May 9, 2023 | $-1.67 | $-3.17 | -89.8% | ✗ MISS |
Q1 2023 | Feb 27, 2023 | — | $-1.76 | — | — |
Q4 2022 | Nov 8, 2022 | $-0.06 | $-1.27 | -2016.7% | ✗ MISS |
Q3 2022 | Aug 1, 2022 | $0.63 | $-0.86 | -236.5% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $0.24 | $0.18 | -25.0% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | — | $-0.07 | — | — |
Latest News
HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $15 Price Target
📈 PositiveEmergent BioSolutions Received FDA Approval For Of Raxibacumab At Winnipeg, Canada Site
📈 PositiveEmergent BioSolutions shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance.
📈 PositiveEmergent BioSolutions shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance.
📈 PositiveEmergent BioSolutions Raises FY2025 Sales Guidance from $765.000M-$835.000M to $775.000M-$835.000M
📈 PositiveEmergent BioSolutions Q3 Adj. EPS $1.06 Beats $0.11 Estimate, Sales $231.100M Beat $199.000M Estimate
📈 PositiveEmergent BioSolutions Receives $29M In Product Orders From An International Government Partner
📈 PositiveEmergent BioSolutions Receives $17M Contract Modification From BARDA For Oral Suspension TEMBEXA; Modification Is Under Existing 10-Year Contract
📈 PositiveEmergent BioSolutions shares are trading higher after the company announced it received a $56 million contract modification to supply ACAM2000 to the US government.
📈 PositiveEmergent BioSolutions Receives $56M Contract Modification To Supply ACAM2000 To US Government
📈 PositiveHC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $15 Price Target
📈 PositiveEmergent BioSolutions Secures $30M BARDA Contract To Supply CYFENDUS Anthrax Vaccine By March 2026
📈 PositiveEmergent BioSolutions discloses CEO stock purchase
📈 PositiveFrequently Asked Questions about EBS
What is EBS's current stock price?
What is the analyst price target for EBS?
What sector is Emergent BioSolutions Inc. in?
What is EBS's market cap?
Does EBS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EBS for comparison